Rubicon Founders purchased 175,142 shares of Privia Health Group; estimated trade size of $3.95 million based on quarterly average pricing.
Post-trade, Rubicon Founders holds 5,948,664 shares valued at $122.36 million.
Privia Health Group now accounts for 88.92% of the fund's reportable AUM, underscoring its significance in the portfolio.
According to an SEC filing dated May 15, 2026, Rubicon Founders LLC increased its holdings in Privia Health Group (NASDAQ:PRVA) by 175,142 shares during the first quarter. The estimated transaction value was $3.95 million, calculated using the average closing prices for the quarter. The quarter-end value of the position fell by $14.53 million, a figure that reflects both the trading activity and changes in share price.
| Metric | Value |
|---|---|
| Revenue (TTM) | $2.25 billion |
| Net income (TTM) | $21.76 million |
| Market capitalization | $2.94 billion |
| Price (as of market close May 14, 2026) | $23.24 |
Privia Health Group is a national healthcare platform specializing in physician enablement and value-based care solutions. The company leverages technology and coordinated care models to support independent providers and medical groups, driving operational efficiency and improved patient experiences.
With a scalable business model and a focus on aligning financial incentives, Privia Health positions itself as a strategic partner for healthcare organizations navigating the shift to value-based care.
Rubicon Founders increasing its stake in Privia Health Group during the first quarter is a noteworthy event for investors. It demonstrates the hedge fund has a bullish outlook towards the stock, so much so that Privia Health now represents nearly 90% of the firm’s AUM. As a result, the fund’s performance depends almost entirely on this one stock.
A deeper look into Privia Health Group’s financials reveals a strong company. It ended 2025 with $2.1 billion in revenue, up an impressive 22% year over year. Its 2025 net income rose 59% over 2024 to $22.9 million. Its balance sheet was outstanding with $1.4 billion in total assets compared to $578.4 million in total liabilities and no debt.
The company followed 2025 with accelerating sales in the first quarter of 2026. Revenue rose 26% year over year to $603.8 million, and Privia Health expects full-year revenue to reach around $2.4 billion.
This performance suggests customers are finding its solutions are fulfilling an unmet need in the healthcare industry, and bodes well for Privia Health’s ongoing success. Consequently, its stock looks like a worthwhile long-term investment.
Before you buy stock in Privia Health Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Privia Health Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $463,900!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,401!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 30, 2026.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.